Morningstar lifts fair value for Australia's ALS on supportive industry trends

ALS

31/03/2026 20:49

** Analysts at Morningstar increase fair value estimate for Australia's ALS Ltd ALQ.AX by 4% to A$16.70

** Investment research firm estimates ALS's FY26 underlying NPAT of A$354 million ($243.84 million), a 15% growth from FY25

** Morningstar remains at the high-end of recently upgraded FY26 organic revenue growth guidance of 6%-8% for the testing services provider

** Tightening regulations and energy transition add to the tailwind for ALS, Morningstar says

** 10 out of 13 analysts rate stock "buy" or higher, 2 "hold" and 1 "sell"; set the median PT at A$24.70 - LSEG data

** ALQ down 5.6% YTD

($1 = 1.4518 Australian dollars)

 (Reporting by Keshav Singh Chundawat in Bengaluru)

 ((Keshav.singhchundawat@thomsonreuters.com))